SNP 610
Alternative Names: SNP-610Latest Information Update: 15 Jun 2023
Price :
$50 *
At a glance
- Originator Sinew Pharma
- Class Drug conjugates; Hepatoprotectants; Immunoconjugates
- Mechanism of Action Enzyme modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
Most Recent Events
- 15 Jun 2023 Phase-II clinical trials in Non-alcoholic steatohepatitis in Taiwan (PO), prior to June 2023 (Sinew Pharma pipeline, June 2023)
- 15 Jun 2023 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO) (Sinew Pharma pipeline, June 2023)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in Taiwan